Last reviewed · How we verify
exogenous indulin injection daily
At a glance
| Generic name | exogenous indulin injection daily |
|---|---|
| Sponsor | S-Evans Biosciences Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- exogenous indulin injection daily CI brief — competitive landscape report
- exogenous indulin injection daily updates RSS · CI watch RSS
- S-Evans Biosciences Co., Ltd. portfolio CI